InvestorsHub Logo
Followers 12
Posts 3841
Boards Moderated 0
Alias Born 04/30/2004

Re: None

Tuesday, 06/14/2022 6:57:46 AM

Tuesday, June 14, 2022 6:57:46 AM

Post# of 1456
B.Riley Financial Thinks Lineage Cell Therapeutics’ Stock is Going to Recover

Source: TipRanks
B.Riley Financial analyst Mayank Mamtani initiated coverage with a Buy rating on Lineage Cell Therapeutics (LCTX – Research Report) today and set a price target of $4.00. The company's shares closed last Monday at $1.30, close to its 52-week low of $1.10. According to TipRanks.com, Mamtani has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -31.4% and a 20.7% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals. Currently, the analyst consensus on Lineage Cell Therapeutics is a Strong Buy with an average price target of $6.00, which is a 334.
https://www.tipranks.com/news/blurbs/b-riley-financial-thinks-lineage-cell-therapeutics-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent LCTX News